National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional )

The summary for the National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional ) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional ): This Funding Opportunity Announcement (FOA) solicits applications for a single Coordinating Center to support novel data acquisition strategies, data harmonization, analysis and dissemination activities on emerging and current drug abuse trends across the United States. The Coordinating Center will (1) Maintain a Scientific Advisory Group; (2) Maintain and refine an Early Warning Network composed of local experts on drug abuse data from the selected communities, as well as NIDA-supported community-based researchers, to assist in the ongoing monitoring and interpretation of data; (3) Maintain key community-level indicators for monitoring drug abuse trends and early identification of new synthetic drugs and emerging issues including establishing harmonization of indicators and of presentation and analysis of indicators across the selected communities; (4) Continue to identify and maintain novel sources of data including treatment admissions data, national drug use among adults and youth, law enforcement seizures, and drug poisoning death; (5) Conduct cross-site data analyses from the harmonized Coordinating Center data; (6) Continue to disseminate and identify novel ways to execute dissemination and publication plans of results and findings from the Coordinating Center data, including development and maintenance of a website for disseminating data and findings; (7) Conduct webinars on topics of interest to stakeholders; (8) Conduct on the ground epidemiologic investigations on topics of immediate crisis or need, providing functional feedback to impacted communities towards optimizing current and future response; (9) Provide operational, administrative and logistical support for the Coordinating Center data harmonization and dissemination initiative.
Federal Grant Title: National Drug Early Warning System Coordinating Center (U01 Clinical Trial Optional )
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-20-016
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.279
CFDA Descriptions: Information not provided
Current Application Deadline: August 14th, 2019
Original Application Deadline: August 14th, 2019
Posted Date: May 31st, 2019
Creation Date: May 31st, 2019
Archive Date: September 19th, 2019
Total Program Funding:
Maximum Federal Grant Award: $550,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: May 31st, 2019
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-016.html
Grant Announcement Contact
NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - C...
Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trials Not ...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com